Ohio is currently home to 3314 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Non-endoscopic Esophageal Sampling to Detect Barrett's Esophagus and Esophageal Cancer in Veterans
NCT05210049
Recruiting
This study seeks to incorporate non-endoscopic detection method (Esocheck/Esoguard) in primary care practice and test whether this screening modality increases the positive predictive value of upper endoscopy and increases the detection of Barrett's esophagus and esophageal cancer.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
12/14/2022
Locations: Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio
Conditions: Barrett Esophagus, GERD, Obesity, Esophageal Cancer
Register for Updates
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
NCT05616728
Recruiting
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
12/06/2022
Locations: Toledo Institute of Clinical Research, Toledo, Ohio
Conditions: COVID-19
Register for Updates
Knee Related Subchondral Bone Lesions Treated With IOBP
NCT05314608
Recruiting
The study will be a prospective, multicenter clinical study evaluating clinical and patient reported outcome measures of subjects receiving IOBP® surgical technique using Angel cPRP and BMA processing system to treat subchondral bone pathology (SBP).
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
12/02/2022
Locations: The Ohio State University, Columbus, Ohio
Conditions: Subchondral Cyst
Register for Updates
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
NCT05545150
Recruiting
This clinical trial assesses if the use of a three-dimensional imaging device called the Clarix Imaging Volumetric Specimen Imager (VSI) can help guide and assist surgeons in identifying and removing all positive margins while in the operating room (intraoperative imaging) for patients with breast cancer and breast ductal carcinoma in situ. Breast conservation surgery or lumpectomy is a standard of care (routine) procedure that removes the tumor and a rim of surrounding normal tissue (margins) w... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/30/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8
Register for Updates
Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections
NCT05633277
Recruiting
Randomized Controlled Trial to determine if the outcomes of sclerotherapy of the ulcer bed alone differ from a combination of ablation and sclerotherapy injections.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2022
Locations: Jobst Vascular Institute, ProMedica Toledo Hospital, Toledo, Ohio
Conditions: Venous Reflux, Venous Insufficiency, Venous Ulcer, Venous Disease
Register for Updates
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT02325674
Recruiting
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Gender:
All
Ages:
All
Trial Updated:
11/23/2022
Locations: Endocrinology Research Associates, Columbus, Ohio
Conditions: Generalised Lipodystrophy, Partial Lipodystrophy
Register for Updates
Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
NCT03711890
Recruiting
This trial studies how well ultra-high resolution optical coherence tomography works in detecting micrometer sized early stage pancreatic cancer in participants with pancreatic cancer. Ultra-high resolution optical coherence tomography may help to accurately identify pancreatic cancer in resected pancreatic specimens.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2022
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Pancreatic Carcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type
Register for Updates
Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)
NCT03476980
Recruiting
An extension of the PREMOD2 trial, the PREMOD2 Follow-Up trial will evaluate the neurodevelopmental outcomes at 22-26 months corrected age of preterm children who received UCM or DCC. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.
Gender:
All
Ages:
Between 22 months and 42 months
Trial Updated:
11/22/2022
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Neurodevelopmental Abnormality
Register for Updates
Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases
NCT05503251
Recruiting
This phase II trial studies the effect of neuropsychological evaluation and intervention in maintaining quality of life after radiation therapy in patients with cancer that has spread to the brain (metastases). Quality of life refers to the overall enjoyment of life. It holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness. Neu... Read More
Gender:
All
Ages:
All
Trial Updated:
11/18/2022
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Register for Updates
TruGraf® Long-term Clinical Outcomes Study
NCT04491552
Recruiting
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Kidney Transplant Rejection
Register for Updates
Let's Know!2: Language-focused Intervention for Children at Risk of Comprehension Difficulties
NCT05133479
Recruiting
In the proposed project, the investigators will conduct a multisite randomized controlled trial (RCT) to determine the efficacy of Let's Know!2, a small-group, language focused comprehension intervention, on children's lower- and higher-level language skills and comprehension skills in the short- and long-term (Specific Aims 1 and 2). The investigators will also explore whether intervention effects are moderated by dosage, initial language skill, developmental language disorder (DLD) status, wor... Read More
Gender:
All
Ages:
Between 5 years and 12 years
Trial Updated:
11/09/2022
Locations: The Ohio State University, Columbus, Ohio
Conditions: Language Disorders in Children
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Aultman Alliance Community Hospital, Alliance, Ohio
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates